Sodium Fluoride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Sodium Fluoride: From Vitamin Deficiency Disorder to Epiglottitis
One-Sentence Summary
Sodium fluoride was originally associated with the treatment of vitamin deficiency disorder (based on the knowledge graph's indication records). The TxGNN model predicts it may be effective for epiglottitis, but there are currently 0 clinical trials and 0 publications supporting this prediction. The prediction is purely computational and has no direct clinical or literature support.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vitamin deficiency disorder (knowledge graph record; the Singapore licence records contain no indication text) |
| Predicted New Indication | Epiglottitis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Sodium fluoride is a fluoride salt used in dental products and as a trace-element component of parenteral nutrition. Its role in vitamin deficiency disorder comes from the knowledge graph and is not confirmed by Singapore labelling.
The predicted indication, epiglottitis, is an acute airway infection usually caused by bacteria such as Haemophilus influenzae type b. It is treated with antibiotics and airway management. No mechanistic link between sodium fluoride and this condition has been established, and the drug has no known antibacterial activity relevant to it.
The high score (99.92%) most likely reflects network proximity to anti-infective drugs in the knowledge graph rather than drug-specific biology. Other top-ranked predictions (urinary tract infection, gonococcal urethritis, Ureaplasma urethritis, urogenital and abdominal tuberculosis) show the same pattern: all are infections with no supporting evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for epiglottitis.
For reference, the closest-ranked laryngeal prediction (laryngitis, rank 7) returned four publications. None of them show therapeutic efficacy: they cover diphtheria toxin modulation in cell culture, fluorine toxicity in broilers, and [18F]NaF PET/CT imaging, including a case report in laryngeal carcinoma. They appear to be keyword matches only.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07802P | DURAPHAT 50mg/ml Dental Suspension | Liquid | Not specified |
| SIN08899P | PEDITRACE Concentrate for Parenteral Infusion | Injection | Not specified |
| SIN15302P | ADDAVEN Concentrate for Solution for Infusion | Infusion, solution concentrate | Not specified |
| SIN14341P | Nutritrace Concentrate for Solution for Infusion | Infusion, solution concentrate | Not specified |
All four registrations are valid single-ingredient licences. The available forms are a dental liquid and injectable or infusion concentrates. Epiglottitis is an acute airway infection, and none of these forms is an established route for treating it.
Safety Considerations
- Contraindications flagged in the knowledge graph (not label text): kidney disease, nephrolithiasis, nephrocalcinosis, acute urate nephropathy, pyoureter, sarcoidosis, hyperparathyroidism, osteitis fibrosa, hypercalcemia, phosphorus metabolism disease, nephrolithiasis susceptibility caused by SLC26A1, constipation disorder, lytic metastatic bone lesion, and dental fluorosis.
No drug-interaction records were found. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is computational only. There are no clinical trials or relevant publications, and no plausible mechanism links sodium fluoride to epiglottitis, which has effective standard antibiotic therapy. The same holds for all other top-10 predictions.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA), which are currently missing and block safety screening
- Mechanism of action data (e.g. from DrugBank)
- Evidence of in vitro or preclinical activity against the relevant pathogens
- Confirmation of the original approved indication, since the licence records contain no indication text
- Assessment of route and formulation compatibility with the proposed use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.